Key result
Milrinone significantly increased left ventricular ejection fraction (MD 5.69; 95% CI 4.27 to 7.10; p<0.00001) and cardiac output, but did not improve survival in acute heart failure after AMI.
Why the study?
Does milrinone improve outcomes in patients with acute heart failure after acute myocardial infarction?
Population
Patients with acute heart failure after acute myocardial infarction
Comparison
Milrinone vs Control group
Design
Meta-analysis
Authors
Loading...
No survival benefit despite LVEF gains in post-AMI acute HF; confirms limited role for milrinone and challenges surrogate-driven use.
Meta-Analysis
Does milrinone improve outcomes in patients with acute heart failure after acute myocardial infarction?
Effect estimate: MD 5.69 (95% CI 4.27 to 7.10)
p-value: p=<0.00001
Milrinone improves hemodynamic parameters such as LVEF and cardiac output in patients with acute heart failure after acute myocardial infarction, but current evidence does not demonstrate a survival benefit.
Tang et al. (2015) conducted a meta-analysis in Acute heart failure after acute myocardial infarction. Milrinone vs. Control was evaluated on Left ventricular ejection fraction (MD 5.69, 95% CI 4.27 to 7.10, p=<0.00001). Milrinone significantly increased left ventricular ejection fraction (MD 5.69; 95% CI 4.27 to 7.10; p<0.00001) and cardiac output, but did not improve survival in acute heart failure after AMI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: